The aim of this study was to clarify the role of serum S100β on the accurate assessment of reversibility of brain damage after fulminant hepatic failure (FHF). Among the 13 patients with FHF enrolled in this study, 12 underwent living donor liver transplantation; one patient could not the procedure because of volvulus of the sigmoid colon. Serum S100β was serially measured using a chemiluminescent immunoassay. Preoperative serum S100β in patients with diffuse brain edema was significantly higher than that in patients with localized brain edema (P < 0.05). Patients with preoperative brain death showed serum S100β levels over 7.0 μg/L. Serum S100β levels correlated with the degree of brain edema of FHF. It has the potential to be a new clinical, noninvasive indicator of brain damage due to FHF.
|Number of pages||4|
|Publication status||Published - Nov 2004|
All Science Journal Classification (ASJC) codes